Showing 1,526 results

Filters Content type: News, Editors' picks Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

New & experimental HIV treatments

European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV

Editor's pick
Gilead press release
25 April 2016
PrEP

Gilead Statement on the Approval of PrEP in Peru

Editor's pick
Gilead Sciences
14 April 2016
Access to healthcare

Innovative new programme set to treat 10,000 patients co-infected with hepatitis C and HIV in Africa and Asia

Editor's pick
World Hepatitis Alliance
14 April 2016
Access to healthcare

PrEP Pricing Problems

Editor's pick
TAG
2 April 2016
Access to healthcare

Greed and the Necessity for Regulation

Editor's pick
TAG
2 April 2016
Pharmaceutical industry

GSK eases IP rights for poorest countries, considers patent pooling for cancer

Editor's pick
Intellectual Property Watch
2 April 2016
Finance & funding

Mortgages For Expensive Health Care? Some Experts Think It Can Work

Editor's pick
Kaiser Health News
29 March 2016
Drug-resistant TB

Just 2% of people with the severest cases of drug-resistant TB currently have access to new, more effective treatments

Editor's pick
Médecins Sans Frontières
24 March 2016
Pharmaceutical industry

Merck Wins Chance for Royalties on Gilead’s Hepatitis C Cure

Editor's pick
Bloomberg
24 March 2016
Access to healthcare

South African activists picket UN meeting for access to medicines

Editor's pick
Health-e
21 March 2016
Pharmaceutical industry

Inside the $100 million ad blitz for a $1100-a-pill drug for hepatitis C

Editor's pick
STAT
9 March 2016
Pharmaceutical industry

Gilead Spars With Merck Over Hepatitis C $1000-Pill Royalties

Editor's pick
Bloomberg
8 March 2016
Access to healthcare

UNITAID study looks at delinking cost of R&D from price of medicines

Editor's pick
UNITAID
2 March 2016
New & experimental HIV treatments

European CHMP Adopts Positive Opinion for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine/Tenofovir Alafenamide) for the Treatment of HIV

Editor's pick
Gilead press release
26 February 2016
Pharmaceutical industry

HIV unit emerges as 'critical' driver of GSK growth

Editor's pick
Financial Times
26 February 2016
Pharmaceutical industry

Bristol-Myers Squibb completes previously announced sale of its HIV R&D portfolio to ViiV Healthcare

Editor's pick
Bristol-Myers Squibb press release
23 February 2016
Pharmaceutical industry

Study finds access to high-priced medicines may differ across EU

Editor's pick
Health Action International
23 February 2016
Pharmaceutical industry

The cost of curing Hepatitis C

Editor's pick
BBC Newsnight / You Tube
18 February 2016
Health services & systems

Progress report on promises made to improve South Africa’s health services

Editor's pick
The Conversation
11 February 2016
Access to healthcare

Pharma company Viiv’s attempt to secure patents for key HIV drugs dolutegravir and cabotegravir opposed in India

Editor's pick
Médecins Sans Frontières
11 February 2016
Testing & health monitoring

Abbott inks $5.8B deal for Alere to expand in point-of-care diagnostics

Editor's pick
Fierce Medical Devices
9 February 2016
New & experimental hepatitis C treatment

Fair Pricing Coalition Recognizes Merck’s Lower Price for Curative Hepatitis C Treatment, Calls for Manufacturers to Reduce Excessive Prices and Increase Patient Assistance

Editor's pick
Fair Pricing Coalition
8 February 2016
HIV prevention policy

Activists United and Ignited by Urgency for HIV Prevention in Europe: EATG and AVAC call for the rollout of PrEP as a proven HIV prevention strategy

Editor's pick
EATG
3 February 2016
PrEP

European Medicines Agency Validates Gilead’s Type II Variation Application for Truvada for Reducing the Risk of Sexually Acquired HIV

Editor's pick
Gilead press release
1 February 2016